CN1083276C - Chinese-medicinal capsule for treating osteonecrosis - Google Patents
Chinese-medicinal capsule for treating osteonecrosis Download PDFInfo
- Publication number
- CN1083276C CN1083276C CN99112482A CN99112482A CN1083276C CN 1083276 C CN1083276 C CN 1083276C CN 99112482 A CN99112482 A CN 99112482A CN 99112482 A CN99112482 A CN 99112482A CN 1083276 C CN1083276 C CN 1083276C
- Authority
- CN
- China
- Prior art keywords
- deal
- accounts
- medicine
- osteonecrosis
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a pure traditional Chinese medicine capsule for treating osteonecrosis, which is mainly composed of three prescriptions of traditional Chinese medicines, wherein the sovereign drug is composed of trimeresurus mucrosquamatus cantor, scorpion and gecko, and occupies 30 to 40% of the total weight; the minister drug is composed of fortune's drynaria rhizome, himalayan teasel root, angelica, pawpaw and hairy antler, and occupies 40 to 50% of the total weight; the adjunctive drug is composed of safflower, olibanum, myrrh and atractylodes rhizome, and occupies 10 to 20% of the total weight. The medicine of the present invention acts on the liver and the kidney, and can obtain the purposes of nourishing the liver and the kidney, activating blood circulation to dissipate blood stasis, dredging the meridian passage, removing the wind, relieving pain, promoting blood transportation recovery of medial femoral circumflex arteries, causing the necrotic bony tissues to liquidize, absorb and regenerate new bones, and radically curing osteonecrosis. The present invention provides a novel pure traditional Chinese medicine for treating osteonecrosis.
Description
The invention belongs to the Chinese medicine development field, exactly belong to the pure Chinese medicinal preparation for the treatment of osteonecrosis.
At present, in the medicine of treatment osteonecrosis, the Western medicine impotentia can only the armrest art be treated.Existing traditional Chinese medical science medicine can only be controlled the partial symptoms of osteonecrosis or keep present situation, does not also have a medicine the liquefaction of necrotic bone tissue can be absorbed, and new bone again regrows.Existing treatment osteonecrosis medicine is based on analgesia, blood circulation promoting and blood stasis dispelling, and these medicines only can arrive in the flesh, and can't guide to the marrow, just can't putrefaction removing and tissue regeneration promoting, do not reach the purpose of healing.Execute by differential diagnosis in tcm and to control: the kidney providing essence-QI to the bone and marrow, bone and marrow are kidney and lead, and the rule of treatment is supported essence with the kidney warming, and that medullization is given birth to is active, and bone growth has foster.All do not work hard at this in all medicines of existing treatment osteonecrosis, so that therapeutic effect is not good, even symptom is recovered to alleviate to some extent, but bone is newborn in fact, and the necrotic area can not get repairing and do not have a real curative effect.
The purpose of this invention is to provide and a kind ofly necrotic bone tissue liquefaction can be absorbed and can regrow new bone and reach the pure Chinese medicine capsule of treatment osteonecrosis disease.
Chinese medicinal capsule of the present invention is made up of three prescription medicines: principal agent is made up of five step jumpings, Du Bai, Gekko Swinhonis that deal is equal to, accounts for the 30-40% of total deal; The medicine accessory drugs is made by Rhizoma Drynariae, Radix Dipsaci, Radix Angelicae Sinensis, Fructus Chaenomelis, Cornu Cervi Pantotrichum, and wherein Rhizoma Drynariae, Radix Dipsaci, Radix Angelicae Sinensis, Fructus Chaenomelis deal equate that the deal of Cornu Cervi Pantotrichum is the 40-50% that 1/3, the second prescription medicine of Rhizoma Drynariae deal accounts for total deal; Adjuvant drug is made up of Flos Carthami, Olibanum, Myrrha, Rhizoma Atractylodis, and wherein Flos Carthami accounts for 1/4 part, and Olibanum accounts for 1/8 part, Myrrha accounts for 1/8 part, and Rhizoma Atractylodis account for 1/2 part, and the 3rd prescription medicine accounts for the 10-20% of total deal, Rhizoma Atractylodis in the 3rd prescription medicine adjuvant drug can be substituted by cattle sunset, also can be substituted by Rhizoma Curcumae Longae.
The present invention adopts that damp eliminating is stimulated the menstrual flow, activating blood circulation to dissipate blood stasis, the benefit of promoting blood circulation marrow, reaches the effect of the blood of regulating the flow of vital energy, invigorating the liver and kidney, the arteries and veins of invigorating blood circulation, strong bone life.Get through the stasis of blood blood vessels that stagnate to walk to scurry sensible medicine (being principal agent), outer the meridian dredging, in reach the internal organs skeleton, all QI and blood cohesion parts all can be opened it, the stagnate thing of necrosis of all stasis of bloods all can be changed it; The medicine (being accessory drugs) that is aided with people's Liver and kidney and stomach warp, expelling wind and removing dampness, dredge the meridian passage, the foster essence of the kidney warming, blood circulation promoting and blood stasis dispelling reaches the purpose of the blood of regulating the flow of vital energy, invigorating the liver and kidney, the arteries and veins of invigorating blood circulation, strong bone life; Assistant with the removing blood stasis pain relieving, be inducted into medicine (being adjuvant drug) and reach pain relieving and separate the stasis of blood through reaching disease institute, the messenger drug walking is goed deep into target and is arrived disease institute.
Medicine of the present invention is returned through Liver and kidney and is reached tonifying liver the kidney invigorating, blood circulation promoting and blood stasis dispelling, dredge the meridian passage, searches that wind relieves the pain, bone and muscle strengthening, promotes to revolve strand interior tremulous pulse recovery blood and transports, and makes necrotic bone tissue fluid absorption, and bone trabecula rearranges neatly, lives again new bone and reaches therapeutic purposes.
After Chinese medicinal capsule of the present invention is taken, all having in one to 15 day local pain to increase the weight of sensation, mainly is that the efficacy of a drug of circulation of qi promoting removing blood stasis forces QI and blood return due to, active the promoting blood circulation, in case unobstructed vessel pain is promptly ended; Pain symptom alleviates after 20 days; The necrotic bone tissue absorbs obviously after four months, and new bone growth is arranged; Light-duty energy rehabilitation after eight months, heavy symptom disappears substantially, and sign obviously changes; Can cure in one to two year.
Medicine of the present invention source is wide, and famous and precious medicine is few, and cost is low, and taking convenience, can fundamentally reach the purpose of curing osteonecrosis, for treatment osteonecrosis disease provides a kind of novel pure Chinese medicine medicine.
Claims (1)
1, a kind of treatment osteonecrosis pure Chinese medicine capsule is characterized in that it is made up of three prescription medicines, and the first prescription medicine principal agent is made by five step jumpings, Du Bai, Gekko Swinhonis that deal is equal to, accounts for the 30-40% of total deal; The second prescription medicine accessory drugs is made by Rhizoma Drynariae, Radix Dipsaci, Radix Angelicae Sinensis, Fructus Chaenomelis, Cornu Cervi Pantotrichum, and wherein Rhizoma Drynariae, Radix Dipsaci, Radix Angelicae Sinensis, Fructus Chaenomelis deal equate that the deal of Cornu Cervi Pantotrichum is the 40-50% that 1/3, the second prescription medicine of Rhizoma Drynariae deal accounts for total deal; The 3rd prescription medicine adjuvant drug is made up of Flos Carthami, Olibanum, Myrrha, Rhizoma Atractylodis, and wherein Flos Carthami accounts for 1/4 part, and Olibanum accounts for 1/8 part, Myrrha accounts for 1/8 part, and Rhizoma Atractylodis account for 1/2 part, and the 3rd prescription medicine accounts for the 10-20% of total deal, Rhizoma Atractylodis in the 3rd prescription medicine adjuvant drug can be substituted by cattle sunset, also can be substituted by Rhizoma Curcumae Longae.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN99112482A CN1083276C (en) | 1999-10-11 | 1999-10-11 | Chinese-medicinal capsule for treating osteonecrosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN99112482A CN1083276C (en) | 1999-10-11 | 1999-10-11 | Chinese-medicinal capsule for treating osteonecrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1291501A CN1291501A (en) | 2001-04-18 |
| CN1083276C true CN1083276C (en) | 2002-04-24 |
Family
ID=5275783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN99112482A Expired - Fee Related CN1083276C (en) | 1999-10-11 | 1999-10-11 | Chinese-medicinal capsule for treating osteonecrosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1083276C (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1199639A (en) * | 1998-06-11 | 1998-11-25 | 赵世华 | Chinese medicine preparation for curing osteonecrosis |
| CN1210005A (en) * | 1997-09-04 | 1999-03-10 | 赵永国 | Medicine for necrosis of femoral head |
| CN1214925A (en) * | 1997-10-22 | 1999-04-28 | 林元珍 | Traditional Chinese medicine tablet for curing fracture and femur head necrosis |
| CN1230424A (en) * | 1998-03-27 | 1999-10-06 | 王秉森 | Recipe and preparation of bone recovering bolus |
-
1999
- 1999-10-11 CN CN99112482A patent/CN1083276C/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1210005A (en) * | 1997-09-04 | 1999-03-10 | 赵永国 | Medicine for necrosis of femoral head |
| CN1214925A (en) * | 1997-10-22 | 1999-04-28 | 林元珍 | Traditional Chinese medicine tablet for curing fracture and femur head necrosis |
| CN1230424A (en) * | 1998-03-27 | 1999-10-06 | 王秉森 | Recipe and preparation of bone recovering bolus |
| CN1199639A (en) * | 1998-06-11 | 1998-11-25 | 赵世华 | Chinese medicine preparation for curing osteonecrosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1291501A (en) | 2001-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1118285C (en) | Shubi plaster for treating arthralgia due to wind-cold-dampness | |
| CN101361872A (en) | Traditional Chinese medicine for quickly treating bone fracture and postoperative nonunion and delayed healing | |
| CN102512630A (en) | Traditional Chinese medicine composition for treating gallbladder calculus | |
| CN102100754A (en) | Chinese medicinal composition for treating osteoproliferation | |
| CN101905006B (en) | External medicament for treating traumatic injury | |
| CN1390585A (en) | Chinese medicine for detoxication purpose and its preparing process | |
| CN1257715A (en) | Tincture for treating rheumatoid arthritis and its preparing process | |
| CN102579634B (en) | Externally applied traditional Chinese medicine composition for treating knee osteoarthritis (OA) | |
| CN101721651B (en) | Traditional Chinese medicine capsule for treating scapulohumeral periarthritis | |
| CN106266896A (en) | A kind of invigorating primordial QI, kidney invigorating and YANG supporting, bone and muscle strengthening, the pill of curing rheumatism | |
| CN101401873A (en) | Medicine plaster for treating furunculosis, exogenous injury and rheumatic arthritis | |
| CN1083276C (en) | Chinese-medicinal capsule for treating osteonecrosis | |
| CN103585483B (en) | Traditional Chinese medicine composition for treating knee osteoarthritis and preparation method of same | |
| CN1259065C (en) | Chinese medicinal preparation for quick bone fracture setting | |
| CN102512543B (en) | Chinese medicinal composition for treating rheumatoid arthritis | |
| CN102430030B (en) | Chinese medicinal composition for treating bone impediment | |
| CN101804179B (en) | Traditional Chinese medicine composition for treating hyperosteogeny of cervical vertebra and lumbar vertebra and preparation method thereof | |
| CN104644952A (en) | Traditional Chinese medicine preparation for treating cold-dampness type chronic lumbar strain | |
| CN1814242A (en) | Medicinal liquor for treating wind-cold, numbness and swelling pain disease | |
| CN1836711A (en) | Chinese traditional medicine for treating rheumatism involving the bone | |
| CN102133380A (en) | Medicament for treating cervical spondylosis | |
| CN105617214A (en) | Traditional Chinese medicine composition for treating scabies | |
| CN105770427A (en) | Traditional Chinese medicine composition for treating oligospermia and asthenozoospermia | |
| CN105663612A (en) | Traditional Chinese medicine composition for treating ankylosing spondylitis | |
| CN1113667C (en) | Medicine for treating rheumatic and rheumatoid diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |